TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7753339

Group type: EXPERIMENTAL
Intervention: Naloxone (125 micrograms/kg) and AVP (10 units) combined administration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg) with naloxone and AVP
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 2396618

Group type: EXPERIMENTAL
Intervention: Gowning group (102 infants)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Nongowning group (100 infants)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 202
Study: 7384169

Group type: EXPERIMENTAL
Intervention: Fructose-1,6-diphosphate (FDP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 30
Study: 31433953

Group type: EXPERIMENTAL
Intervention: Diet with DCAD of 0 mEq/kg DM
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diet with DCAD of -40 mEq/kg DM
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control diet with DCAD of 85 mEq/kg DM
Number of subjects: 8
Study: 31337172

Group type: EXPERIMENTAL
Intervention: 5-Hz rTMS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 60
Study: 27053335

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1‐8% in oxygen by face mask)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Thiopental sodium (25 mg/kg administered rectally)
Number of subjects: 21
Study: 26141305

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of r-hFSH plus r-hLH (Pergoveris)
Number of subjects: 946

Group type: COMPARATOR
Intervention: r-hFSH monotherapy (GONAL-f)
Number of subjects: 946
Study: 23358057

Group type: EXPERIMENTAL
Intervention: Supportive text messages delivered twice daily for three months
Number of subjects: 26
Study: 21333087

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion during pressure support ventilation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo infusion during pressure support ventilation
Number of subjects: 14
Study: 19296179

Group type: EXPERIMENTAL
Intervention: SEE IT intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 17122228

Group type: EXPERIMENTAL
Intervention: Automated external defibrillators (AED) under the influence of electromagnetic fields (EMF)
Number of subjects: 390
Study: 15606399

Group type: EXPERIMENTAL
Intervention: Ultrase MT12 (12,000 lipase units per capsule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrase MT20 (20,000 lipase units per capsule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11416689

Group type: EXPERIMENTAL
Intervention: Use of low-dose aspirin, calcium, or other dietary supplements for the prevention of pre-eclampsia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management considerations for chronic hypertension and pregnancy-specific conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of K5 for determining diastolic pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elimination of edema as a criterion for diagnosing pre-eclampsia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure increases of 30 mm Hg systolic or 15 mm Hg diastolic as a diagnostic criterion
Number of subjects: 0
Study: 9135770

Group type: EXPERIMENTAL
Intervention: Pyrantel
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 7983226

Group type: EXPERIMENTAL
Intervention: Desensitization treatment to lessen dietary restraint anxiety
Number of subjects: 49

Group type: COMPARATOR
Intervention: Relaxation training (control group)
Number of subjects: 49
Study: 2607227

Group type: EXPERIMENTAL
Intervention: Cervical spine rotation during leg length measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flat and hi-low tables during leg length measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galvanic paravertebral muscle stimulation during leg length measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cervically lesioned subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interrater and intrarater reliability measurements
Number of subjects: 0
Study: 31660848

Group type: EXPERIMENTAL
Intervention: Bi-clustering tree ensembles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional tree-ensemble methods (ERT and RF)
Number of subjects: 0
Study: 28475737

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 787
Study: 26004162

Group type: EXPERIMENTAL
Intervention: Goserelin (GnRHa) 3.6 mg implant
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 23615868

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) 4 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: GXR and LDX in combination
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (GXR or LDX alone)
Number of subjects: 42
Study: 21853822

Group type: EXPERIMENTAL
Intervention: Pharmacists attending consultant-led ward rounds in addition to providing a ward pharmacy service
Number of subjects: 5

Group type: COMPARATOR
Intervention: Pharmacists providing a ward pharmacy service alone
Number of subjects: 5
Study: 19953774

Group type: EXPERIMENTAL
Intervention: Two-step etch&rinse adhesive system (Single Bond, 3M ESPE)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Two-step self-etch adhesive (Clearfil SE Bond, Kuraray)
Number of subjects: 33
Study: 17111469

Group type: EXPERIMENTAL
Intervention: Spinal hyperbaric ropivacaine 10.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spinal hyperbaric ropivacaine 12 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spinal hyperbaric ropivacaine 13.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spinal hyperbaric ropivacaine 15 mg
Number of subjects: 60
Study: 15575447

Group type: EXPERIMENTAL
Intervention: AmF toothpaste (1250 ppm F‐) plus AmF mouthrinse (250 ppm F‐)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sodium monofluorophosphate dentifrice (1250 ppm F‐)
Number of subjects: 84

Group type: COMPARATOR
Intervention: AmF dentifrice (1250 ppm F‐)
Number of subjects: 84

Group type: COMPARATOR
Intervention: NaMFP toothpaste (1250 ppm F‐) plus NaMFP varnish (1250 ppm)
Number of subjects: 84
Study: 11182337

Group type: EXPERIMENTAL
Intervention: Neoadjuvant estramustine (10 mg/kg/day) and etoposide (50 mg/m2/day) for three cycles, followed by radical prostatectomy.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neoadjuvant estramustine and etoposide treatment.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neoadjuvant estramustine and etoposide treatment followed by radical prostatectomy.
Number of subjects: 18
Study: 9216132

Group type: EXPERIMENTAL
Intervention: Closed-loop drug infusion using arbutamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated delivery of arbutamine
Number of subjects: 0
Study: 7965851

Group type: EXPERIMENTAL
Intervention: Maximal exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Minimal exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (sitting on a bicycle)
Number of subjects: 8
Study: 3524307

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally and metoclopramide 10 mg intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally and metoclopramide 20 mg intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29725868

Group type: EXPERIMENTAL
Intervention: velmanase alfa
Number of subjects: 33
Study: 27093976

Group type: EXPERIMENTAL
Intervention: Pixantrone 50 mg/m(2) intravenously combined with rituximab 375 mg/m(2) intravenously on day 1, for up to six cycles.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m(2) intravenously combined with rituximab 375 mg/m(2) intravenously on day 1, for up to six cycles.
Number of subjects: 0
Study: 25672163

Group type: EXPERIMENTAL
Intervention: Calcium polystyrene sulphonate (CPS)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sodium polystyrene sulphonate (SPS)
Number of subjects: 97
Study: 23325717

Group type: EXPERIMENTAL
Intervention: Passive Recovery (PR) for 25-s duration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Passive Recovery (PR) for 50-s duration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Active Recovery (AR) for 25-s duration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Active Recovery (AR) for 50-s duration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Passive Recovery (PR) for 100-s duration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Active Recovery (AR) for 100-s duration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Passive Recovery (PR) for 25-s and 50-s durations
Number of subjects: 8

Group type: COMPARATOR
Intervention: Active Recovery (AR) for 25-s and 50-s durations
Number of subjects: 8
Study: 21875410

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 0
Study: 18194522

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention involving extended training in risk assessment, risk communication, decision aid, and motivational interviewing; 2 consultations and 1 follow-up telephone call.
Number of subjects: 720

Group type: COMPARATOR
Intervention: Usual care by nurses in the control arm after risk estimation according to the national guideline.
Number of subjects: 720
Study: 16484111

Group type: EXPERIMENTAL
Intervention: Relational condition (apprehended as lying on the other member)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Independent condition (apprehended as independent objects)
Number of subjects: 0
Study: 12938827

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg at bedtime
Number of subjects: 14
Study: 10732179

Group type: EXPERIMENTAL
Intervention: Computer-aided treatment (high technology)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Traditional brush machine treatment (low technology)
Number of subjects: 47
Study: 8617896

Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Tai Chi maintenance
Number of subjects: 110
Study: 1633517

Group type: EXPERIMENTAL
Intervention: Spontaneous ascites filtration
Number of subjects: 35

Group type: COMPARATOR
Intervention: Total paracentesis plus intravenous albumin infusion
Number of subjects: 35
Study: 6367811

Group type: EXPERIMENTAL
Intervention: clenbuterol
Number of subjects: 39

Group type: COMPARATOR
Intervention: flavoxate hydrochloride
Number of subjects: 39
Study: 31783136

Group type: EXPERIMENTAL
Intervention: Sheng-Hua-Tang (SHT) 200 mg/kg orally for seven consecutive days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sheng-Hua-Tang (SHT)
Number of subjects: 0
Study: 31751400

Group type: EXPERIMENTAL
Intervention: Community-based action teams to change social norms on gender and violence; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 28903842

Group type: EXPERIMENTAL
Intervention: ≤3 Mets of physical activity (chest physiotherapy, sitting over edge of bed, standing and sitting on chair at bedside) on zero postoperative day
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conventional treatment on first postoperative day
Number of subjects: 174
Study: 25649209

Group type: EXPERIMENTAL
Intervention: QMF149 (indacaterol maleate 500 µg/MF 400 µg)
Number of subjects: 1519

Group type: COMPARATOR
Intervention: MF (400 µg)
Number of subjects: 1519
Study: 25059121

Group type: EXPERIMENTAL
Intervention: Interactive web-based intervention including Healthy Heart Profile and calorie restricted diet
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard information on dietary intake and physical activity via the study website
Number of subjects: 160
Study: 22584133

Group type: EXPERIMENTAL
Intervention: Insulin suspension activated by the LGS function
Number of subjects: 3128
Study: 19520247

Group type: EXPERIMENTAL
Intervention: Various interventions used in randomized clinical trials for AHFS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17383995

Group type: EXPERIMENTAL
Intervention: Intravenous dopamine (5 microg/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous dopamine (10 microg/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no dopamine)
Number of subjects: 12
Study: 15555218

Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study: 11768276

Group type: EXPERIMENTAL
Intervention: Individually tailored treatment (n = 38)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Standard Chinese herbal formulation (n = 43)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (n = 35)
Number of subjects: 116
Study: 9513798

Group type: EXPERIMENTAL
Intervention: Primary Closed Angle Glaucoma (PCAG) subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of normal subjects
Number of subjects: 0
Study: 8067219

Group type: EXPERIMENTAL
Intervention: Solcotrans
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 3231285

Group type: EXPERIMENTAL
Intervention: Surgery within 72 hours post subarachnoid hemorrhage (SAB)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Surgery at later intervals
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Overall surgical treatment
Number of subjects: 115
Study: 31291977

Group type: EXPERIMENTAL
Intervention: jin acupuncture group
Number of subjects: 166

Group type: COMPARATOR
Intervention: pseudo acupuncture group
Number of subjects: 166
Study: 29107679

Group type: EXPERIMENTAL
Intervention: Selective internal radiotherapy (SIRT) with yttrium-90 resin microspheres
Number of subjects: 467

Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 467
Study: 25321951

Group type: EXPERIMENTAL
Intervention: Wavefront-guided (WFG) PRK treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Wavefront-optimized (WFO) PRK treatment
Number of subjects: 71
Study: 22716199

Group type: EXPERIMENTAL
Intervention: Patient-centered collaborative care (CC)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard collaborative care (CC)
Number of subjects: 132
Study: 21480032

Group type: EXPERIMENTAL
Intervention: Preventive intervention (FRIENDS program, cognitive-behavioral anxiety intervention)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Wait list comparison group (control)
Number of subjects: 98
Study: 18345020

Group type: EXPERIMENTAL
Intervention: Pea protein hydrolysate (PPH)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Whey protein (WP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Milk protein (MP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Whey protein + pea protein hydrolysate (WP+PPH)
Number of subjects: 39
Study: 17139217

Group type: EXPERIMENTAL
Intervention: Circumferential lumbar fusion
Number of subjects: 148

Group type: COMPARATOR
Intervention: Posterolateral lumbar fusion
Number of subjects: 148
Study: 12685616

Group type: EXPERIMENTAL
Intervention: niacin ER/lovastatin 2,000/40 mg
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: niacin ER/lovastatin
Number of subjects: 237

Group type: COMPARATOR
Intervention: lovastatin 40 mg
Number of subjects: 237
Study: 10881247

Group type: EXPERIMENTAL
Intervention: OXC 2400 mg/day
Number of subjects: 79

Group type: COMPARATOR
Intervention: OXC 300 mg/day
Number of subjects: 79
Study: 9192926

Group type: EXPERIMENTAL
Intervention: Sidestream nebulizer driven by CR50 air compressor
Number of subjects: 173

Group type: COMPARATOR
Intervention: Hudson nebulizer and Pulmo‐Aide compressor
Number of subjects: 173
Study: 1587075

Group type: EXPERIMENTAL
Intervention: 60 mg sustained-release fenfluramine plus 15 mg phentermine resin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo added to behavior modification, caloric restriction, and exercise
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Initial receipt of medication (fenfluramine plus phentermine)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Active medication (fenfluramine plus phentermine)
Number of subjects: 52
Study: 4028808

Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline ('Trental' 400) 3 times daily for 8 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2 mg co-dergocrine mesylate 3 times daily for 8 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 90
Study: 29428925

Group type: EXPERIMENTAL
Intervention: Diaphragm pacemaker (DP) plus YiqiDitanTongfu (YDTF) decoction
Number of subjects: 287

Group type: COMPARATOR
Intervention: Diaphragm pacemaker (DP)
Number of subjects: 287
Study: 30938581

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Standardized patients
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study: 30103444

Group type: EXPERIMENTAL
Intervention: High Mediterranean diet score
Number of subjects: 2568

Group type: COMPARATOR
Intervention: Low Mediterranean diet score
Number of subjects: 2568
Study: 26924405

Group type: EXPERIMENTAL
Intervention: Ablative fractional carbon dioxide laser combined with intradermal platelet-rich plasma treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ablative fractional carbon dioxide laser with intradermal normal saline
Number of subjects: 16
Study: 24565103

Group type: EXPERIMENTAL
Intervention: Sheathed speculum
Number of subjects: 136
Study: 22853873

Group type: EXPERIMENTAL
Intervention: Psycho-educational group intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 100
Study: 19874728

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antihistamines, antihistamine‐decongestant combinations, guaifenesin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antihistamines, decongestants, DM, or combinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zinc
Number of subjects: 0
Study: 17360720

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) based on the FRAMES protocol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Simple Advice (SA)
Number of subjects: 90
Study: 14612894

Group type: EXPERIMENTAL
Intervention: Gemcitabine (standard schedule)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gemcitabine (fixed dose rate schedule)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gemcitabine (both schedules)
Number of subjects: 50
Study: 11087784

Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (single infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 9195523

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 17
Study: 1534166

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 11

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 11
Study: 3896594

Group type: EXPERIMENTAL
Intervention: Ovo-lacto-vegetarian (OLV) diet for 6 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual diet maintained for 12 weeks
Number of subjects: 58
Study: 31431683

Group type: EXPERIMENTAL
Intervention: Continuous-value risk model
Number of subjects: 5105

Group type: EXPERIMENTAL
Intervention: Point-based model
Number of subjects: 5105

Group type: EXPERIMENTAL
Intervention: Validation of risk model
Number of subjects: 5105
Study: 30178038

Group type: EXPERIMENTAL
Intervention: ddMVAC
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: gemcitabine-cisplatin
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: gemcitabine-carboplatin
Number of subjects: 824

Group type: COMPARATOR
Intervention: ddMVAC vs gemcitabine-cisplatin
Number of subjects: 824
Study: 27275059

Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral diazepam
Number of subjects: 60
Study: 25273343

Group type: EXPERIMENTAL
Intervention: Bevacizumab and capecitabine (bevacizumab 15 mg/kg on day 1; capecitabine 1000 mg/m2 twice per day on days 1-14, every 3 weeks)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Bevacizumab only (15 mg/kg on day 1)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Bevacizumab and capecitabine
Number of subjects: 185

Group type: COMPARATOR
Intervention: Bevacizumab only
Number of subjects: 185
Study: 22497823

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 19934097

Group type: EXPERIMENTAL
Intervention: Modified catheters (MC) with SMA coating
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional catheters (CC)
Number of subjects: 16
Study: 17869409

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Open prostatectomy (OP)
Number of subjects: 120
Study: 15767470

Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg) for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg) for 12 weeks
Number of subjects: 18
Study: 12925422

Group type: EXPERIMENTAL
Intervention: Anticoagulation clinics
Number of subjects: 221

Group type: COMPARATOR
Intervention: Family physicians
Number of subjects: 221
Study: 11272364

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy using the Galileo Centering Catheter
Number of subjects: 312
Study: 9139273

Group type: EXPERIMENTAL
Intervention: Plasma ACE activity in patients with mild and moderate hypertension
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasma ACE activity in patients with left ventricular hypertrophy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasma ACE activity and left ventricular mass indexes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasma ACE activity and blood pressure levels
Number of subjects: 50